#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Thrombotic microangiopathy Dementia Haemophilia A with anti factor VIII Rheumatoid arthritis Fibrosarcoma Warm autoimmune haemolytic anaemia Indolent systemic mastocytosis Rhabdoid tumour Acquired C1 inhibitor deficiency Mucopolysaccharidosis II Osteogenesis imperfecta Lennox-Gastaut syndrome Congenital growth hormone deficiency Vaginal cancer Retinitis pigmentosa More trials…

    Learn about Rare Diseases

    Haemophagocytic lymphohistiocytosis – Treatment Ewing’s sarcoma Mastocytosis – Life with Disease Hereditary optic atrophy – Trials in Disease Systemic mastocytosis Marfan’s syndrome – Basic Information Shprintzen-Goldberg syndrome – Basic Information Bronchopulmonary dysplasia – Life with Disease Breast angiosarcoma metastatic – Basic Information Marfan’s syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ammonium Chloride ZODASIRAN Atomoxetine Hydrochloride ARGININE GLUTAMATE Mifamurtide PHENTOLAMINE MESILATE Potassium Nms-03305293 Sevoflurane Lanifibranor Clazakizumab Triamcinolone Hexacetonide Ivospemin Carfilzomib Azacitidine Tapentadol Hydrochloride Amivantamab Paracetamol Ph. Eur. 204-NETU Cabergoline More therapies…

    Learn about Your Condition

    Hypochromic anaemia Diphtheria Subdural haematoma Neoplasm malignant Pituitary tumour benign Plasma cell myeloma recurrent Chronic sinusitis Tendon injury Triple positive breast cancer Substance use disorder Immune-mediated myositis Pharyngeal cancer stage III Respiratory failure Ovarian cancer recurrent Primary hyperaldosteronism More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Johanniter GmbH Johanniter-Krankenhaus

Johanniter GmbH Johanniter-Krankenhaus

Johanniterstrasse 3-5, Zentrum, Bonn, 53113, Germany

Want to learn more about this study or check if you can participate? Contact us.

  • Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Apalutamide
    • Docetaxel
    France Germany Italy Portugal Spain

  • A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Bladder cancer
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • (S)-4-(4-(3-CHLORO-4-(1-(5-FLUOROPYRIDIN-2-YL)-2-HYDROXYETHOXY)PYRAZOLO[1,5-A]PYRIDIN-6-YL)-5-METHYL-1H-1,2,3-TRIAZOL-1-YL)PIPERIDINE-1-CARBONITRILE
    • Enfortumab Vedotin
    • Pembrolizumab
    Czechia Denmark France Germany Hungary Italy +3

  • A Study of Pembrolizumab and Radiotherapy for Patients with Early-Stage Favorable Classic Hodgkin Lymphoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hodgkin’s disease
    Investigated Drugs:
    • Pembrolizumab
    Germany

  • A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

    Recruiting

    4 1
    Investigated Diseases:
    • Cachexia
    Investigated Drugs:
    • VISUGROMAB
    Bulgaria Czechia France Germany Ireland Italy +5

  • A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Ivonescimab
    • Bevacizumab
    • Fluorouracil
    Belgium Czechia France Germany Hungary Italy +2

  • Study Comparing Zilovertamab Vedotin with Drug Combination for Untreated Patients with Diffuse Large B-Cell Lymphoma

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Polatuzumab Vedotin
    • Zilovertamab Vedotin
    • Cyclophosphamide
    Belgium Germany Ireland Italy Poland

  • Study on Ponatinib and Imatinib for Adults with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Acute lymphocytic leukaemia
    Investigated Drugs:
    • Imatinib
    • Ponatinib
    • Blinatumomab
    Germany

  • Study on Chemotherapy with Irinotecan, Fluorouracil, and Oxaliplatin for Patients with Metastatic Colorectal Cancer After Surgery or Ablation

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Disodium Folinate
    • Calcium Folinate Pentahydrate
    • Irinotecan Hydrochloride Trihydrate
    Germany

  • Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Iberdomide
    • Dexamethasone
    • Isatuximab
    Austria Germany

  • Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Datopotamab Deruxtecan
    • Infliximab
    • Mycophenolate Mofetil
    Austria Belgium Germany Hungary Italy Poland +1
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!